Clinical trials suggested that YSJB ameliorated symptoms of RA patients and decreased rheumatic factor (RF), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) (Li et al., 2008; Zhang et al., 2011). The gene discussed is CRP; the disease is rheumatoid arthritis.